ArticleFrontiers in oncology2026
Ultrasound-based shrinkage patterns at mid-neoadjuvant chemotherapy for predicting pathological complete response in invasive breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop an ultrasound-based tumor shrinkage pattern and subsequently construct a predictive model for pathological complete response by analyzing changes in ultrasonic features and measurements at mid-treatment of neoadjuvant chemotherapy (NAC) in invasive breast cancer, ultimately evaluating its clinical applicability. Methods: This study included all breast cancer patients who underwent NAC and subsequent surgery between January 2017 and December 2024. All patients received breast ultrasound examinations before and during NAC. All breast tumor images were reviewed by two experienced sonographers, who assessed and documented the ultrasound characteristics of the tumors. Based on the comparison of parameter changes, the tumors were classified into two patterns: centripetal shrinkage (CS) and non-centripetal shrinkage (NCS). NCS was further subdivided into four patterns: echogenic change, partial shrinkage, dendritic shrinkage, and fragmentation. According to the postoperative pathological results, patients were categorized into two groups: the pathological complete response (pCR) group and the non-pCR group. Univariate analysis and multivariate logistic regression analysis were performed to identify independent predictors for the predictive model. A nomogram was constructed, and receiver operating characteristic curves were plotted to evaluate the model's performance. Results: The study included a total of 287 lesions. The results of the logistic shrinkage analysis indicated CS, ΔS(the rate of area change), echogenicity changes, Adler decrease, HER-2 positivity, and Ki-67 were identified as independent predictors of pCR (all P< 0.05). The nomogram model based on these factors demonstrated areas under the curve of 0.906 (95% CI = 0.866 - 0.946) in the training set and 0.850 (95%CI = 0.770 - 0.929) in the testing set. The univariate model using only the shrinkage pattern (CS vs NCS) yielded an AUC of 0.741 (95% CI: 0.680 - 0.803). Conclusion: It is feasible to establish tumor shrinkage patterns based on ultrasound examinations during the mid-NAC stage. The nomogram-based predictive model, which combines ultrasound image changes and tumor pathological indicators, can predict NAC outcomes and holds certain clinical application value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.